You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Suppliers and packagers for NOXAFIL POWDERMIX KIT


✉ Email this page to a colleague

« Back to Dashboard


NOXAFIL POWDERMIX KIT

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Msd Merck Co NOXAFIL POWDERMIX KIT posaconazole FOR SUSPENSION, DELAYED RELEASE;ORAL 214770 NDA Merck Sharp & Dohme LLC 0085-2224-02 8 PACKET in 1 CARTON (0085-2224-02) / 1 POWDER, FOR SUSPENSION in 1 PACKET (0085-2224-01) 2021-06-08
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: NOXAFIL POWDERMIX KIT

Last updated: August 3, 2025


Introduction

The pharmaceutical landscape for antifungal therapy hinges on the availability of reliable suppliers for essential medication components. NOXAFIL POWDERMIX KIT, a formulation comprising the active ingredient posaconazole, offers an important prophylactic and treatment option for invasive fungal infections. Ensuring access to high-quality suppliers for this kit demands understanding the manufacturing, distribution, and regulatory landscapes influencing supply chains.


Overview of NOXAFIL POWDERMIX KIT

NOXAFIL POWDERMIX KIT contains dry powder form of posaconazole, intended to be reconstituted with a diluent prior to intravenous administration, or as a precalibrated oral suspension. Its formulation and packaging are critical to drug stability and bioavailability. The kit's design aligns with strict pharmaceutical standards, including sterile manufacturing and validated logistic pathways.


Key Manufacturers and Suppliers

1. Pfizer Inc.

As the originator of NOXAFIL (posaconazole), Pfizer remains the primary supplier globally. The pharmaceutical giant maintains comprehensive manufacturing units across North America, Europe, and Asia, ensuring consistent supply of NOXAFIL POWDERMIX KITS (also marketed under brand names like Noxafil). Pfizer’s integrated supply chain adheres to cGMP standards, guaranteeing product quality and regulatory compliance.

  • Production Capacity: Pfizer’s manufacturing facilities are equipped for large-scale production, aligning with global demand, especially amidst the COVID-19 pandemic surge.
  • Distribution Network: Extensive distribution agreements with regional wholesalers, hospitals, and pharmacies facilitate worldwide access.

2. Dr. Reddy’s Laboratories

While primarily known for generics, Dr. Reddy’s manufactures and supplies posaconazole formulations, including powder and suspension kits, under licensing agreements with Pfizer in certain markets. Their manufacturing plants in India and other regions serve as critical supply sources for developing countries and regions with limited Pfizer presence.

  • Quality Assurance: Dr. Reddy’s adheres to global quality standards, including WHO GMP certifications, facilitating regulatory approval in multiple countries.
  • Market Focus: Strong presence in emerging markets like India, Southeast Asia, and Latin America.

3. Teva Pharmaceutical Industries

Teva offers generic versions of posaconazole or similar antifungal formulations, including powderkits in select markets. Their robust global manufacturing infrastructure offers an alternative source, particularly where Pfizer’s supply is constrained.

  • Supply Reliability: Teva’s widespread manufacturing network in Israel, Europe, and North America enhances supply stability.
  • Regulatory Compliance: Ensures adherence to international quality standards, including FDA and EMA approvals.

4. Other Regional Suppliers and Contract Manufacturers

Emerging pharmaceutical players, particularly in Asia and Eastern Europe, are increasingly acquiring licensing rights or engaging in contract manufacturing of antifungal drugs, including NOXAFIL POWDERMIX KIT components.

  • Examples: Firm-specific licensing agreements authorize regional manufacturers to produce and distribute under local regulatory frameworks.
  • Quality Considerations: Variable, requiring due diligence based on certifications and third-party audits.

Supply Chain and Regulatory Considerations

Securing a reliable supply hinges on understanding regional regulatory environments and global supply chain dynamics. The following points are fundamental:

  • Regulation and Approval: Ensure suppliers possess requisite approvals from agencies like the FDA (USA), EMA (Europe), or respective national agencies.
  • Manufacturing Certifications: Verify compliance with cGMP standards to mitigate risks of substandard or counterfeit products.
  • Supply Chain Resilience: Evaluate suppliers' logistics capacities to maintain supply continuity amidst global disruptions, such as pandemics or geopolitical instability.

Emerging Trends and Future Outlook

  • Local Manufacturing Initiatives: Governments and pharmaceutical companies aim to localize production, reducing dependency on international supply chains.
  • Generic and Biosimilar Competition: The expiration of patents may lead to increased competition, potentially lowering costs and expanding access.
  • Digital Supply Chain Management: Adoption of blockchain and IoT systems enhances transparency and traceability, improving supplier verification processes.

Conclusion

Securing the supply chain for NOXAFIL POWDERMIX KIT involves strategic partnerships with reputable global manufacturers like Pfizer, alongside regional generic producers such as Dr. Reddy’s and Teva. Rigorous due diligence on regulatory compliance, manufacturing quality, and logistical robustness is paramount. As demand persists, innovative manufacturing and supply chain resilience will be pivotal to ensuring continuous access to this essential antifungal medication.


Key Takeaways

  • Primary Supplier: Pfizer remains the main supplier of NOXAFIL POWDERMIX KIT worldwide, backed by extensive manufacturing and distribution capabilities.
  • Regional Alternatives: Generics from companies such as Dr. Reddy’s and Teva serve as vital alternatives, especially in emerging markets.
  • Regulatory and Quality Standards: Verify that suppliers meet global standards (FDA, EMA, WHO GMP) to ensure product safety and efficacy.
  • Supply Chain Vigilance: Assess suppliers' logistics infrastructure and resilience, particularly in unstable geopolitical or economic environments.
  • Future Trends: Focus on localization, biosimilars, and supply chain digitization to enhance availability and affordability.

FAQs

1. Who are the main global suppliers of NOXAFIL POWDERMIX KIT?
Pfizer Inc. is the primary manufacturer worldwide. Regional generic manufacturers such as Dr. Reddy’s and Teva supply alternatives in specific markets.

2. Can regional generics fully substitute the original NOXAFIL POWDERMIX KIT?
Yes, provided they meet the same regulatory standards and quality certifications, these generics can serve as effective alternatives.

3. What regulatory considerations should buyers verify when sourcing from suppliers?
Ensure suppliers hold approvals from agencies like FDA, EMA, or local authorities and adhere to cGMP standards.

4. How are supply chain disruptions affecting NOXAFIL availability?
Global disruptions, such as pandemics or geopolitical issues, can impact manufacturing and distribution, underscoring the need for diversified supplier networks.

5. What future developments could influence the supply landscape for NOXAFIL?
Increased regional manufacturing, biosimilar competition, and supply chain digitalization will shape the availability and pricing of NOXAFIL POWDERMIX KIT.


Sources

  1. Pfizer Inc. [Official Website].
  2. World Health Organization (WHO). WHO GMP Certification Standards.
  3. Dr. Reddy’s Laboratories. Product Information.
  4. Teva Pharmaceutical Industries. Product Portfolio.
  5. Pharmaceutical Business News, Industry Reports (2022).

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.